Immunic (IMUX) announced the outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, ...

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing ...

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis 22.10.2024 / 12:30 CET/CEST The issuer is solely responsible ...

Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical ...

As a member of the nuclear receptor (NR) superfamily of ligand-dependent transcription factors, HNF4α has two highly conserved domains for DNA binding (DBD) and ligand binding (LBD) and binds DNA as a ...

Liver X receptor beta (LXRβ) shows potential in reducing depression and anxiety by improving neurogenesis, reducing ...

The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Berlin, Germany-based Ariceum Therapeutics presented promising preclinical data at EANM 2024 on its radiop5Ac-satoreotide for ...

Topical retinoids (for example, tretinoin) and retinoid analogues (for example, adapalene and tazarotene) help normalize hyperkeratinization and have demonstrated significant anti-inflammatory ...

LXRβ, a nuclear receptor initially known for its role in cholesterol metabolism and inflammation, is now emerging as a crucial player in neuroscience and psychiatry. The review synthesizes recent ...

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease ...

This classical mode of action as a nuclear receptor takes minutes to hours. "Estrogen also can change the firing activity of neurons in a manner of milliseconds, but it was not clear how this ...